Janux Therapeutics
Clinical trials sponsored by Janux Therapeutics, explained in plain language.
-
New hope for Hard-to-Treat prostate cancer: JANX007 enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug, JANX007, in men with metastatic castration-resistant prostate cancer that has worsened after other treatments. The main goals are to check safety and find the right dose. About 272 participants will receive the drug to see if it can help c…
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated May 26, 2026 02:25 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-stage study tests a new drug, JANX014, in 43 men with a hard-to-treat type of prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The main goals are to check the drug's safety and find the right dose, while also looking …
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for advanced cancers: JANX008 enters first human trials
Disease control Recruiting nowThis early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (like lung, kidney, breast, or colorectal cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shri…
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
First human trial launches for experimental autoimmune drug
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called JANX011 in 60 healthy adults to see if it is safe and how the body processes it. The goal is to gather information that could help treat autoimmune diseases in the future. Participants receive one or more doses and are monitored clos…
Phase: EARLY_PHASE1 • Sponsor: Janux Therapeutics • Aim: Knowledge-focused
Last updated May 08, 2026 12:03 UTC